by William Lazonick and Öner Tulum On August 16, 2022, Congress passed the Inflation Reduction Act, which, among other things, enables Medicare to negotiate the prices of certain high-cost prescription drugs, beginning in 2026.[1] Even though it is just one…
Tag: Oner Tulum
# 12. Who controls the supply of COVID-19 vaccines, and why does it matter?
by Öner Tulum, William Lazonick, Ken Jacobson, and Ellen Chappelka Nine months after the US Food and Drug Administration (FDA) granted emergency use authorization (EUA) to the first of…
#10. Scaling of COVID vaccine manufacturing: Dose selection, stability, and optimization of mRNA-based COVID vaccines
by Öner Tulum, William Lazonick, and Ken Jacobson This is the final installment of a three-part series on the scalability of mRNA vaccine production. The current article focuses…
#9. Scaling of COVID vaccine manufacturing: Procuring lipids and assembling lipid nanoparticles
by Öner Tulum, William Lazonick, and Ken Jacobson This is the second installment of a three-part series on the scalability of mRNA vaccine production. The current article focuses…
#8. Scaling of COVID vaccine manufacturing: It’s all about the lipids
by Öner Tulum, William Lazonick, and Ken Jacobson This is the first installment of a three-part series on the scalability of mRNA vaccine production. The current article focuses…
#7. Scaling of COVID vaccine manufacturing: What are the problems that can occur in the early stages?
by Öner Tulum, William Lazonick, and Ken Jacobson In March 2020, as a number of developers announced COVID-vaccine candidates that would begin clinical trials, vaccine manufacturers around the…
#6. Scaling of COVID vaccine manufacturing: Does the CEO understand the extraordinary complexities involved?
by Öner Tulum, William Lazonick, Ken Jacobson, and Ellen Chappelka During an interview on December 18, 2020, Moderna CEO Stéphane Bancel revealed his “Never Again Plan,” which…
#5. Scaling of COVID vaccine manufacturing: What manufacturing activities are involved and why are they so difficult?
by Öner Tulum, William Lazonick, and Ken Jacobson In March and April 2021, Americans received as many as four million doses a day of COVID-19 vaccines, far…
#3. Where do those COVID vaccines come from?
by Öner Tulum, William Lazonick, and Ken Jacobson The success of the worldwide COVID-vaccine rollout depends on decisions regarding the utilization of available production capacity made both independently…
#2. How effectively is global capacity being utilized? Is there any idle capacity to press into service?
by Öner Tulum, William Lazonick, and Ken Jacobson Despite vaccines’ significant public-health benefits, sales of all vaccines accounted for less than four percent of $872 billion in prescription-drug…